a higher Ki67 labeling index and aberrant expression of p53, RB, and p16 proteins are more frequent in porocarcinoma (see Diagnosis of porcarcinomas). Dermatoscopy, particularly when revealing a "leaf- and flower-like pattern" in a skin tumor, has been used as a strong indicator that the lesion is a poroma, but confirmation of this diagnosis ultimately relies on histopathological analyses.There is no clear-cut evidence that diagnosing a poromas variant type carries any clinical or therapeutic significance. Treatment
Superficial poroma tumors have been treated by shaving (i.e. removal using a sharp razor) or electrosurgical destruction. Deeper lesions have been removed by excisional biopsy (i.e. a procedure in which an entire tumorous or suspicious area is removed) or simple surgical excision. Since poromas are almost always benign tumors and rarely recur  after their removal, these treatments are in general curative. See also
Porocarcinoma
Hidradenoma


== References ==
In addition to its reactivity to gut-associated lymphoid tissues, Act-1 antibody also stains large numbers of lymphocytes in rheumatoid synovium, and has been shown by Dr. A. A. Ansari of Emory University to prevent or delay onset of AIDS in a monkey-model of Simian Immunodeficiency Virus-induced AIDS. Thus, reactivity with this antibody may show widespread applicability in inflammatory processes of diverse etiologies. Society and culture
Legal status
Takeda filed a Marketing Authorization Application (MAA) in the European Union on 7 March 2013 and a Biologic License Application (BLA) with the U.S. Food and Drug Administration on 21 June 2013 for both Crohns disease and ulcerative colitis. On 4 September 2013, vedolizumab was given a Priority Review Status, which functions to expedite potential acceptance to market.In March 2014, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for vedolizumab (brand name Entyvio).In May 2014, vedolizumab (Entyvio) was approved by the FDA for treatment of both moderate-to-severe ulcerative colitis and moderate-to-severe Crohns disease. In May 2014, Entyvio was approved for medical use in the European Union. In April 2015, Health Canada approved Entyvio. Research
Vedolizumab eventually completed a number of phase III clinical trials for Crohns Disease and Ulcerative Colitis (GEMINI I, GEMINI II, and GEMINI III) that demonstrate that vedolizumab is an effective and well tolerated drug.